AlphAIAlphAI — Financial news for AI agents
investing.comNOV 42 min read$MIRM

H.C. Wainwright raises Mirum Pharmaceuticals price target to $202

H.C. Wainwright raised its price target on Mirum Pharmaceuticals (MIRM) to $202, citing strong Q3 2026 sales of $185.7M, up 40% YoY. LIVMARLI sales reached $133.4M, up 45% YoY. The company's revenue grew 44% over the last year with an 82% gross margin. Despite a wider-than-expected loss, other analysts also raised price targets, noting commercial strength and pipeline progress.

Original reporting
investing.com
Published Nov 4, 2026, 12:40 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 12:54 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$MIRM
Bullish
high confidence
Mentioned
$MIRM
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$MIRMBullishMed
01

Why it matters

The earnings beat and analyst upgrade provide a fresh catalyst that could drive short‑term price appreciation.

02

Market read

New earnings data and analyst upgrade create a timely trading opportunity for MIRM.

03

What to watch

Higher operating expenses and a lower cash balance may constrain near‑term growth.

Relevance 7/10Novelty 7/10Timing: today

Background

Mirum Pharmaceuticals (NASDAQ:MIRM) announced its Q3 2026 results, showing a 40% YoY revenue increase and a price‑target raise by H.C. Wainwright.

Company-level read

Ticker impact

$MIRMBullishHigh confidence
Context

Mirum Pharmaceuticals reported Q3 2026 sales of $185.7M beating estimates and H.C. Wainwright raised its price target to $202.

Expected impact

likely upward pressure as investors price in the higher target and revenue beat

Evidence & confidence

The combination of a strong revenue beat and an analyst price‑target increase typically drives buying interest.

Market effects

Sector

Positive earnings may lift the biotech sector, especially companies with similar oncology pipelines.

Regional

U.S. biotech stocks could see modest gains in early trading.

Global

Limited to investors tracking U.S. biotech earnings.

Counterpoint

What could challenge this read

The earnings miss on EPS and widening loss could temper enthusiasm despite revenue beat.

Key entities

  • company
    Mirum Pharmaceuticals

    Biopharma focused on rare lung diseases.

  • analyst_firm
    H.C. Wainwright

    Raised price target for MIRM to $202.

Read at source← All news

StoryH.C. Wainwright lifts Mirum Pharmaceuticals price target to $202

Related articles

NOV 4
$MIRMMed

Citizens raises Mirum Pharmaceuticals price target on pipeline progress

Citizens raised its price target for Mirum Pharmaceuticals (MIRM) to $167 from $144, citing Livmarli's growth and a diversified pipeline. The company reported 44% revenue growth and 81.7% gross margin. Mirum's Q3 2026 revenue of $185.7M beat estimates, though it posted a wider-than-expected loss per share. The stock has a Strong Buy consensus with targets ranging from $118 to $200.

investing.com2 min
NOV 4
$MIRMMed

Mirum Pharmaceuticals Inc (MIRM) Q3 2026 Earnings Call Highlights: Raised Guidance

Mirum Pharmaceuticals (MIRM) raised its full-year guidance, citing broad-based growth, with adult PFIC as the biggest driver. Q3 saw elevated R&D expenses and minimal Takeda purchases of Livmarli. The company faces regulatory uncertainty for Belixabat and potential revenue headwinds. Management expects continued quarterly revenue growth of $10M-$15M through 2027, with key data readouts planned for Q1 2027.

finance.yahoo.com3 min
NOV 4
$MIRMHighAI 8/10

Mirum Pharmaceuticals Q3 Earnings Call Highlights

Mirum Pharmaceuticals reported Q3 revenue growth of $10M-$15M, expecting this trend to continue through 2027. ATEBRIOZ, approved in September, began U.S. launch with positive early feedback. The company anticipates multiple regulatory submissions in 2027. Mirum ended Q3 with $500M in cash and expects R&D expenses to decline to 10% of revenue long-term.

finance.yahoo.com3 min
NOV 3
$MIRMMedAI 8/10

Mirum Pharmaceuticals Q3FY26 Results: Sales rise 40%, guidance beats estimates

Mirum Pharmaceuticals reported Q3FY26 net product sales of $186M, up 40% YoY. The company raised full-year guidance to $715M-$720M, beating estimates. Livmarli drove growth, with adult PFIC as a key driver. Operating expenses were $245M, with R&D at 50% of revenue. Cash position is ~$500M. The company plans several regulatory milestones and expects cash flow positivity next year.

scanx.trade5 min